No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes

Diabetologia. 2011 Oct;54(10):2736-8. doi: 10.1007/s00125-011-2273-7. Epub 2011 Aug 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / genetics*
  • Glyburide / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Infant, Newborn
  • Mutation
  • Potassium Channels, Inwardly Rectifying / genetics*

Substances

  • Hypoglycemic Agents
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying
  • Glyburide